ClinicalTrials.gg
WithdrawnNCT00754949Updated Nov 22, 2021

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

A Phase 3 interventional study of 1% Azithromycin and 0.1% Dexamethasone and 1% Azithromycin in Blepharoconjunctivitis, sponsored by Sun Pharmaceutical Industries Limited. Withdrawn. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.

02

Conditions studied

  • Blepharoconjunctivitis

Keywords

  • Blepharoconjunctivitis,
  • Ophthalmology
03

In context

Lead sponsor

Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of blepharoconjunctivitis
  • Must be willing to discontinue contact lens wear for the duration of the study
  • Have best corrected visual acuity of 6/24 in both eyes
  • Have IOP less than or equal to 25 mmHg in either eye

Exclusion criteria

Exclusion Criteria:

  • Have known sensitivity or poor tolerance to any component of the study medications
  • Have a history of eyelid and/or ocular surgery and/or have had ocular surgical intervention within 6 months prior to visit 1 or during the study and/or a history of refractive surgery within 6 months
  • Have worn contact lenses 72 hours prior to visit 1 and/or need to wear contact lenses for the duration of the study
  • Have used any topical ophthalmic solutions including tear substitutes within 2 hours of enrollment
  • Use of any eye make-up during the study
  • Have any uncontrolled systemic disease or debilitating disease
  • Have been diagnosed with glaucoma
  • Have any cardiovascular disorders
  • Have any history of liver or kidney disease resulting in persisting dysfunction
  • Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an drug or device
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    Drug: 1% Azithromycin and 0.1% Dexamethasone

  • Active comparator
    2

    Drug: 1% Azithromycin

  • Active comparator
    3

    Drug: 0.1% Dexamethasone

Interventions

  • Drug1% Azithromycin and 0.1% Dexamethasone

    Drug pages: Azithromycin · Dexamethasone

    Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

    Also known as: AzaSite Plus

  • Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

    Also known as: AzaSite

  • Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

    Also known as: Dexamethasone

06

What researchers measure

Primary outcomes

  1. Resolution of the clinical signs and symptoms.

    Time frame: 2 weeks

Secondary outcomes

  1. Bacterial eradication

    Time frame: 2 weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00754949
First posted
Sep 18, 2008
Last update
Nov 22, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azithromycin · Dexamethasone

Start the discussion